 Driving development of XCARTTM platform and leveraging academic collaborations through preclinical development Recent clinical, regulatory and commercial advancements from licensing partners leveraging PolyXen platform technology FRAMINGHAM, MA ACCESSWIRE March 17, 2021 Xenetic Biosciences, Inc. NASDAQ:XBIO Xenetic or the Company, a biopharmaceutical company focused on advancing XCARTTM, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today reported its financial results for the fourth quarter and full year 2020, and provided a corporate update. Notwithstanding the challenges presented by the COVID-19 pandemic, 2020 was a year of significant progress for the Company, including the establishment of partnerships and academic collaborations and advancement in our development efforts, in particular with respect to CAR design and model cell line development, as well as the strengthening of our financial position. 